Intravitreal Injections-related Anxiety
Study Details
Study Description
Brief Summary
Intravitreal injection of Ranibizumab (Lucentis, Genentech) is clinically indicated for patients with wet age-related macular degeneration (AMD) An disadvantage of this technique is the anxiety and discomfort which patients often experience due to the idea of "getting a needle in the eye". In addition, a recent case study indicated the importance of patient education in achieving positive outcomes from intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents. The purpose of our study is to determine whether visual education on AMD and intravitreal injection can reduce patients' anxiety prior to the treatment, and lessen the impact of socioeconomical status on their understanding of the treatment and prognosis.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2/Phase 3 |
Detailed Description
The use of intravitreal injections of Ranibizumab (Lucentis, Genentech) is becoming increasing common for the management of age-related macular degeneration (AMD). It is therefore important to acknowledge and address patients' anxiety due to anticipated discomfort from the idea of "getting a needle in the eye". In addition, visual provision of information at diagnosis concerning long-term treatment expectation may enhance the informed consent process. The use of visual aids may also accommodate patients of different educational background when presented with new and complex treatment information. The purpose of our study is to determine whether visual education on AMD and intravitreal injection can reduce patients' anxiety prior to the treatment, and lessen the impact of socioeconomical status on their understanding of the treatment and prognosis. Although this tool will be developed in the context of injection-requiring retinal diseases, it has applications in the care of disease requiring long-term treatments.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| No Intervention: Control group AMD-related information is not given to patients randomized to the control group. |
|
| Active Comparator: Video materials Educational materials are presented in through a video (audio and visual) |
Behavioral: Video
AMD-related information is presented as in the form of a video
|
| Active Comparator: Print materials Educational materials are presented in the format of printed brochure (visual) |
Behavioral: Printed materials
AMD-related information is presented to patients in the form of a brochure (i.e. printed materials)
|
Outcome Measures
Primary Outcome Measures
- Anxiety [Cross-sectional study, where questionnaires will be completed on the same day of clinic visit.]
Secondary Outcome Measures
- Knowledge of AMD [Cross-sectional study, where questionnaires will be completed on the same day of clinic visit.]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18 years and older
-
AMD patients requiring intravitreal injections
Exclusion Criteria:
-
Unable to read or comprehend English
-
Any contraindications to intravitreal injections, such as IOP elevations
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Toronto Western Hospital | Toronto | Ontario | Canada | M5T 2S8 |
Sponsors and Collaborators
- University Health Network, Toronto
Investigators
- Principal Investigator: Wai-Ching Lam, University Health Network, Toronto
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- UHN-110463AE